Pharma Report 2012: Get Back in Shape

Share this article:
Pharma Report 2012: Get Back in Shape
Pharma Report 2012: Get Back in Shape

13    Bristol-Myers Squibb    $10.9B     up 11.2%
Global revenue: $21.2B (11th); up 8.7%

R&D spend: $3.6B (11th), up 5.9%; 17.0% of rev.

Top brands: Plavix ($6.8B), Abilify ($5.2B), Avapro ($952M), Sustiva ($940M)

Planned launches: Eliquis (SPAF); brivanib (onc.); necitumumab (onc.)

Promotional spend: $906M (7th); 8.3% of rev.

Patent expirations: Plavix (2012), Avapro (2012), Abilify (2015)

Bernstein analyst Tim Anderson forsees eight years of flattish growth for BMS. Among the reasons: losing exclusivity of blockbuster drug Plavix this month and pushback from the FDA, which wants more information about its diabetes contender dapagliflozin, which, if approved, would join a crowded market. On tap is the blood thinner Eliquis—the FDA delayed review for this drug, as well, by three months. The firm's recent strategy has included buying biotech Inhibitex in February 2012 and Amira in September 2011, as well as jettisoning non-pharmaceutical brands. Anderson says the sell-offs have made BMS the most “pure play” pharmaceutical company he covers in the US and Europe.

Back to first page

Page 13 of 21
Share this article:

Email Newsletters

More in Features

Read the complete April 2014 Digital Edition

Read the complete April 2014 Digital Edition

Click the above link to access the complete Digital Edition of the April 2014 issue of MM&M, with all text, charts and pictures.

Antidote: Are e-cigarettes safe?

Antidote: Are e-cigarettes safe?

The pros and cons of e-cigarettes

Combating concept churn

Combating concept churn

There's no cure. But the good news is that prophylaxis is possible.